Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Individual InvestingForge MarketplaceFind new private company investment opportunities​Browse CompaniesInstitutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Data solutionsForge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Index solutionsForge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Forge Thematic BasketsExplore focused views into key private market themesLiquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All insights Reports and highlights News and trends Private market education Tips and tutorials Forge Investment OutlookPrivate Market UpdatesIPO calendarEmerging trendsPrivate company newsUpcoming IPOsAll guidesPrivate market basicsPrivate shares transactionsValuations, pricing and market trendsSelling in the private marketFAQsGlossaryCompany page and tradesProof of ownershipBid and ask submissionsForge fund offeringsInsights About UsLeadershipPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Attovia

Attovia IPO

$368.16M
Series C Valuation, Apr 2025
Register for details
For more details on financing and valuation of private companies similar to Attovia before its IPO, register or log in today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Log In

Attovia IPO date and status

2023
Founded
Jul 2026
S-1 Filed
Aug 2026
IPO Completed

Company details

Attovia is a biotechnology company which offers therapeutic solutions to pharmaceutical companies and healthcare providers. Their platform utilizes a biparatopic nanobody approach in developing potential therapies for complex diseases. By focusing on previously untreatable conditions, Attovia strives to advance drug discovery and provide innovative solutions for unmet medical needs. This company was founded by Tao Fu, Yuling Luo Ph.D, Hangjun Zhan Ph.D, David Bellovin Ph.D, and Petter Veiby Ph.D in 2023 and is headquartered in Fremont, CA.
Founded
2023
Headquarters
Fremont, CA, United States
Forge Price 1
Price not available
Market Activity 2
Limited
Last Matched Price
Post-Money Valuation 3
$368.16M
Total Funding
$255.85M
Last Funding Round
Series C

Learn more about Attovia

To invest in Attovia pre-IPO

Can you invest in Attovia pre-IPO?

You may invest in Attovia as it is a public company listed on the NASDAQ with ticker ATTO. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Attovia before it goes public?

You can no longer sell shares of Attovia on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Attovia shares?

Forge can no longer determine the value of Attovia shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Attovia a publicly traded company?

Attovia became a public company following its IPO on 08/05/2026 and is now traded on the NASDAQ under the ticker ATTO.

To learn more about Attovia potential IPO

Will Attovia go IPO?

Attovia became a public company following its IPO on 08/05/2026 and is now traded on the NASDAQ under the ticker ATTO.

What is Attovia’s IPO price?

The IPO price of Attovia is not currently available.

When was Attovia founded?

Attovia was founded in 2023.

What is Attovia funding to date?

Attovia has raised $255.85M to date.

Attovia major investors

Alamar Biosciences

Attovia pre-IPO valuation and funding rounds

Funding history chart
Funding round and deals details
Funding Date Round Amount Raised Price per Share Post-Money Valuation 3 Key Investors
04/15/2025 Series C $90M $12.77 $368.16M Cormorant Asset Management, Deep Track Capital, Ecor1 Capital, Frazier Life Sciences, Goldman Sachs, Illumina Ventures, Marshall Wace, Mirae Asset Capital, Nextech Ventures, Sanofi Ventures, Venbio, Vida Ventures
Price per Share
$ xx.xx
Shares Outstanding
7,045,699
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Cormorant Asset Management, Deep Track Capital, Ecor1 Capital, Frazier Life Sciences, Goldman Sachs, Illumina Ventures, Marshall Wace, Mirae Asset Capital, Nextech Ventures, Sanofi Ventures, Venbio, Vida Ventures
05/09/2024 Series B $105M $12.77 $273.65M Cormorant Asset Management, Ecor1 Capital, Frazier Life Sciences, Goldman Sachs, Illumina Ventures, Logos Capital, Marshall Wace, Nextech Ventures, Redmile Group, Venbio
Price per Share
$ xx.xx
Shares Outstanding
8,219,982
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Cormorant Asset Management, Ecor1 Capital, Frazier Life Sciences, Goldman Sachs, Illumina Ventures, Logos Capital, Marshall Wace, Nextech Ventures, Redmile Group, Venbio
06/20/2023 Series A-2 $30.42M $10.22 $159.73M Frazier Life Sciences, Illumina Ventures, Venbio
Price per Share
$ xx.xx
Shares Outstanding
2,977,297
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Frazier Life Sciences, Illumina Ventures, Venbio
06/20/2023 Series A-1 $30.43M $9.29 $159.73M Frazier Life Sciences, Illumina Ventures, Venbio
Price per Share
$ xx.xx
Shares Outstanding
3,275,027
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
Frazier Life Sciences, Illumina Ventures, Venbio

Attovia IPO news and media highlights

Independent IPO news coverage

Attovia Therapeutics Raises $90M in Series C Financing

Attovia Therapeutics, a San Carlos, CA-based clinical-stage biopharma company, raised $90M in Series C funding.

Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies

Bay Area–based Attovia Therapeutics announced Thursday it has secured a $105 million Series B as it looks to advance assets in the hot immunology and inflammation space. According to biotech entrepreneur Andrew Pannu, the immunology and inflammation (I&I) sector saw $12.3 billion in therapeutic M&A activity last year and would continue to be attractive to investors. In addition, I&I biotech Apogee Therapeutics closed an upsized public offering in March, netting around $483 million.

Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform

Attovia Therapeutics, a biotech company pioneering spatially optimized biparatopic biologics, announced the closing of the $30 million second tranche of its previously reported $60 million Series A financing. Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 Attobody. Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND-enabling studies, and to further develop the Attobody platform and early discovery pipeline.

Private companies exploring an IPO

See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.

Sector: Healthcare
Subsector: Biotech & Pharma
Trade Metrics Last Funding Round
Company Forge Price Last Matched Round Post-Money Valuation 3 Price Per Share Amount Raised
OURAOURANot available$ xx.xxSeries E$11B$53.57$900M
Affinia TherapeuticsAffinia TherapeuticsNot available$ xx.xxSeries C$156.61M$1.62$40M
OriginOriginNot available$ xx.xxNot available------

Private market movers

Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.

Top Gainers

Company Forge Price (6M Change) Market Activity Last Matched
Ayar Labs Ayar Labs $89.26 +$59.46 (199.53%)Limited $xxx.xx
Kalshi Kalshi $962.28 +$629.16 (188.87%)High $xxx.xx
SandboxAQ SandboxAQ $41.35 +$26.10 (171.15%)High $xxx.xx
SambaNova Systems SambaNova Systems $78.81 +$47.82 (154.31%)High $xxx.xx
Stoke Space Stoke Space $119.38 +$69.46 (139.14%)Limited $xxx.xx

Artificial Intelligence (AI)

Company Forge Price Market Activity Last Matched
Hugging Face Hugging Face Not availableLimited $xxx.xx
OpenAI OpenAI $721.85 +$0.15 (0.02%)High $xxx.xx
Anthropic Anthropic Not availableMedium $xxx.xx
Anduril Anduril $122.93 -$0.11 (0.09%)High $xxx.xx
Databricks Databricks $264.90 +$22.86 (9.44%)High $xxx.xx

Forge, your trusted partner for pre-IPO insights and Attovia data

Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

Updated on: Aug 20, 2026

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.